HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart‐Cussac(Hospital Arnau de Vilanova), Javier Cortés(Vall d'Hebron Institute of Oncology), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Patricia Galván(Vall d'Hebron Institute of Oncology), Begoña Bermejo(Hospital Clínico Universitario de Valencia), Noelia Martínez-Jáñez(Hospital Universitario Ramón y Cajal), María Vidal(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Sònia Pernas, Rafael López‐López(Complejo Hospitalario Universitario de Santiago), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Paolo Nucíforo, Serafín Morales(Hospital Universitari Arnau de Vilanova), Mafalda Oliveira(Vall d'Hebron Hospital Universitari), Lorena de la Peña, Alexandra Peláez, Aleix Prat(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Cited by 339
Abstract
Related Papers
No related papers found
Powered by citation graph analysis